

Barbara A Rath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/86985/publications.pdf>

Version: 2024-02-01

63
papers

4,584
citations

218677

26
h-index

118850

62
g-index

65
all docs

65
docs citations

65
times ranked

6273
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence, Disease Severity, and Follow-Up of Influenza A/A, A/B, and B/B Virus Dual Infections in Children: A Hospital-Based Digital Surveillance Program. <i>Viruses</i> , 2022, 14, 603.	3.3	0
2	Linking digital surveillance and in-depth virology to study clinical patterns of viral respiratory infections in vulnerable patient populations. <i>IScience</i> , 2022, 25, 104276.	4.1	1
3	Access to Vaccination among Disadvantaged, Isolated and Difficult-to-Reach Communities in the WHO European Region: A Systematic Review. <i>Vaccines</i> , 2022, 10, 1038.	4.4	23
4	Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. <i>The Lancet Global Health</i> , 2021, 9, e33-e43.	6.3	71
5	Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2021, 9, e1077-e1087.	6.3	30
6	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 356-366.	4.0	17
7	Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. <i>The Lancet Global Health</i> , 2020, 8, e497-e510.	6.3	235
8	Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 181.	3.9	41
9	Update on current views and advances on RSV infection (Review). <i>International Journal of Molecular Medicine</i> , 2020, 46, 509-520.	4.0	36
10	Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. <i>The Lancet Global Health</i> , 2019, 7, e1031-e1045.	6.3	266
11	Molecular Evolution of Human Adenovirus (HAdV) Species C. <i>Scientific Reports</i> , 2019, 9, 1039.	3.3	101
12	Partnering for enhanced digital surveillance of influenza-like disease and the effect of antivirals and vaccines (PEDSIDEA). <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 309-318.	3.4	16
13	Public perception and vaccine efficacy for influenza: an interview with Barbara Rath, Vienna Vaccine Safety Initiative. <i>Future Virology</i> , 2019, 14, 573-576.	1.8	0
14	Using a mobile application to detect health needs among children and adolescents who are newly arrived migrants in Europe. <i>Journal of Public Health</i> , 2019, 41, 840-849.	1.8	6
15	Incidence, Severity and Impact of Influenza: a joint meeting organised by the ISIRV Epidemiology Group and ECDC, Stockholm, 2019. <i>Eurosurveillance</i> , 2019, 24, .	7.0	6
16	A comparative analysis of psychological trauma experienced by children and young adults in two scenarios: evacuation after a natural disaster vs forced migration to escape armed conflict. <i>Public Health</i> , 2018, 158, 163-175.	2.9	28
17	Can we distinguish respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature review. <i>Reviews in Medical Virology</i> , 2018, 28, e1997.	8.3	38
18	Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data. <i>Vaccine</i> , 2017, 35, 1972-1983.	3.8	35

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 155-164.	1.6	10
20	Educating parents about the vaccination status of their children: A user-centered mobile application. <i>Preventive Medicine Reports</i> , 2017, 5, 241-250.	1.8	32
21	Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 545-568.	4.4	26
22	Prospective Surveillance of Antiviral Resistance in Hospitalized Infants Less than 12 Months of Age with A(H3N2) Influenza Infection and Treated with Oseltamivir. <i>Antiviral Therapy</i> , 2017, 22, 515-522.	1.0	6
23	Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1328-1334.	5.8	67
24	Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. <i>The Lancet Global Health</i> , 2017, 5, e984-e991.	6.3	180
25	Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. <i>Lancet</i> , 2017, 390, 946-958.	13.7	1,634
26	Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study. <i>Drug Safety</i> , 2016, 39, 977-988.	3.2	8
27	The importance of the patient voice in vaccination and vaccine safety—are we listening?. <i>Clinical Microbiology and Infection</i> , 2016, 22, S146-S153.	6.0	34
28	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 192-204.	3.4	54
29	Acute Disseminated Encephalomyelitis After Human Parechovirus Infection. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 35-38.	2.0	12
30	An Inception Cohort Study Assessing the Role of Pneumococcal and other Bacterial Pathogens in Children with Influenza and ILI and a Clinical Decision Model for Stringent Antibiotic Use. <i>Antiviral Therapy</i> , 2016, 21, 413-424.	1.0	15
31	Enabling Precision Medicine With Digital Case Classification at the Point-of-Care. <i>EBioMedicine</i> , 2016, 4, 191-196.	6.1	26
32	Safety, Virology and Pharmacokinetics of Oseltamivir in Infants with Laboratory-Confirmed Influenza: A Phase I/II, Prospective, Open-Label, Multicentre Clinical Trial. <i>Antiviral Therapy</i> , 2015, 20, 815-825.	1.0	7
33	A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤ 24 months. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 286-296.	1.9	12
34	Human Parechovirus Infections Associated with Seizures and Rash in Infants and Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1049-1055.	2.0	29
35	The Impact of the Parent-Physician Relationship on Parental Vaccine Safety Perceptions. <i>Current Drug Safety</i> , 2015, 10, 16-22.	0.6	25
36	Editorial (Thematic Issue: Communicating Vaccine Safety - The Vienna Vaccine Safety Initiative). <i>Current Drug Safety</i> , 2015, 10, 3-4.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Communicating Vaccine Safety to the Media and General Public. <i>Current Drug Safety</i> , 2015, 10, 80-86.	0.6	5
38	Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. <i>Journal of Global Health</i> , 2015, 5, 020416.	2.7	205
39	Vaccine Safety Monitoring Systems in Developing Countries: An Example of the Vietnam Model. <i>Current Drug Safety</i> , 2015, 10, 60-67.	0.6	3
40	A Design Thinking Approach to Effective Vaccine Safety Communication. <i>Current Drug Safety</i> , 2015, 10, 31-40.	0.6	34
41	Teaching Vaccine Safety Communication to Medical Students and Health Professionals. <i>Current Drug Safety</i> , 2015, 10, 23-26.	0.6	16
42	Controlled Language and Information on Vaccines: Application to Package Inserts. <i>Current Drug Safety</i> , 2015, 10, 41-48.	0.6	5
43	Global lessons from Nigeria's ebolavirus control strategy. <i>Expert Review of Vaccines</i> , 2015, 14, 1397-1400.	4.4	8
44	Evaluation of novel second-generation RSV and influenza rapid tests at the point of care. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 171-176.	1.8	26
45	Standardization and simplification of vaccination records. <i>Expert Review of Vaccines</i> , 2014, 13, 545-559.	4.4	14
46	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , 2014, 2, 395-404.	10.7	527
47	Awareness and Utilization of Reporting Pathways for Adverse Events Following Immunization: Online Survey Among Pediatricians in Russia and Germany. <i>Paediatric Drugs</i> , 2014, 16, 321-330.	3.1	6
48	Quantitative Influenza Follow-Up Testing (QIFT) – A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care. <i>PLoS ONE</i> , 2014, 9, e92500.	2.5	14
49	Rotavirus Encephalitis With Basal Ganglia Involvement in an 8-Month-Old Infant. <i>Clinical Pediatrics</i> , 2013, 52, 260-264.	0.8	8
50	Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis. <i>BMC Infectious Diseases</i> , 2013, 13, 1.	2.9	231
51	Introducing new vaccines in developing countries. <i>Expert Review of Vaccines</i> , 2013, 12, 1465-1478.	4.4	43
52	Towards a Personalised Approach to Managing Influenza Infections in Infants and Children – Food for Thought and a Note on Oseltamivir. <i>Infectious Disorders - Drug Targets</i> , 2013, 13, 25-33.	0.8	8
53	In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis. <i>PLoS ONE</i> , 2013, 8, e61102.	2.5	12
54	Persistence versus Reversion of 3TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance. <i>Viruses</i> , 2012, 4, 1212-1234.	3.3	3

#	ARTICLE	IF	CITATIONS
55	Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 899-905.	2.0	27
56	Early detection of influenza A and B infection in infants and children using conventional and fluorescence-based rapid testing. <i>Journal of Clinical Virology</i> , 2012, 55, 329-333.	3.1	41
57	Prioritizing polio. <i>Expert Review of Vaccines</i> , 2012, 11, 1389-1392.	4.4	5
58	Safety reporting in developing country vaccine clinical trialsâ€”A systematic review. <i>Vaccine</i> , 2012, 30, 3255-3265.	3.8	19
59	Adverse Respiratory Symptoms and Environmental Exposures among Children and Adolescents following Hurricane Katrina. <i>Public Health Reports</i> , 2011, 126, 853-860.	2.5	37
60	Evaluating the Brighton Collaboration case definitions, aseptic meningitis, encephalitis, myelitis, and acute disseminated encephalomyelitis, by systematic analysis of 255 clinical cases. <i>Vaccine</i> , 2010, 28, 3488-3495.	3.8	11
61	Persistent <i>Bordetella bronchiseptica</i> Pneumonia in an Immunocompetent Infant and Genetic Comparison of Clinical Isolates with Kennel Cough Vaccine Strains. <i>Clinical Infectious Diseases</i> , 2008, 46, 905-908.	5.8	35
62	â€œAll that palsies is not Bell's [1]â€”The need to define Bell's palsy as an adverse event following immunization. <i>Vaccine</i> , 2007, 26, 1-14.	3.8	36
63	Adverse Health Outcomes after Hurricane Katrina among Children and Adolescents with Chronic Conditions. <i>Journal of Health Care for the Poor and Underserved</i> , 2007, 18, 405-417.	0.8	71